Document is current
Any future updates will be listed below
-
Authors
Wang, Jiawei
Liu, Yujing
Li, Hongyu
Nguyen, Tuan P.
Soto-Vargas, John Lee
Wilson, Rashaun
Wang, Weiwei
Lam, TuKiet T.
Zhang, Chi
Lin, Chen
,
Alvarez, Victor E.
Benedek, David
Che, Alicia
Cruz, Dianne A.
Davis, David A.
Hoffman, Ellen
Huber, Bertrand R.
Kaye, Alfred
Labadorf, Adam T.
Keane, Terence M.
Logue, Mark W.
McKee, Ann
Marx, Brian
Miller, Mark W.
Noller, Crystal
Montalvo-Ortiz, Janitza
Pierce, Meghan
Scott, William K.
Schnurr, Paula
DiSano, Krista
Stein, Thor
Ursano, Robert
Williamson, Douglas E.
Wolf, Erika J.
Lewis, David A.
Glausier, Jill
Holtzheimer, Paul E.
Friedman, Matthew J.
Williams, Kenneth R.
Picciotto, Marina R.
Nairn, Angus C.
Krystal, John H.
Duman, Ronald S.
Young, Keith A.
Zhao, Hongyu
Girgenti, Matthew J.
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (DA018343, DA060811)
U.S. Department of Veterans Affairs (VISN1 Career Development Award)
Brain and Behavior Research Foundation (Young Investigator Award)
American Foundation for Suicide Prevention (Young Investigator Award)
- License Information
-
More Information
Article History
Received: 16 May 2024
Accepted: 14 April 2025
First Online: 29 April 2025
Declarations
:
: The human postmortem brain tissue samples used in this study were provided by the University of Pittsburgh’s NIMH, NICHD, and NINDS Brain and Tissue Repository (Pittsburgh NBTR). All experiments and analyses involving human postmortem samples were conducted in accordance with the Declaration of Helsinki and received approval from the Institutional Review Board of the University of Pittsburgh (MODCR19080015 - 016) as well as the Committee for Oversight of Research and Clinical Training Involving Decedents at the University of Pittsburgh (CORID No. 474).
: Not applicable.
: J.H.K. has consulting agreements (less than US$10,000 per year) with the following: Aptinyx, Inc. Biogen, Idec, MA, Bionomics, Limited (Australia), Boehringer Ingelheim International, Epiodyne, Inc., EpiVario, Inc., Janssen Research & Development, Jazz Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc.; is the co-founder for Freedom Biosciences, Inc.; serves on the scientific advisory boards of Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc. (Clinical Advisory Board), Cerevel Therapeutics, LLC, Delix Therapeutics, Inc., Eisai, Inc., EpiVario, Inc., Jazz Pharmaceuticals, Inc., Neumora Therapeutics, Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, PsychoGenics, Inc., Takeda Pharmaceuticals, Tempero Bio, Inc., Terran Biosciences, Inc.; has stock options with Biohaven Pharmaceuticals Medical Sciences, Cartego Therapeutics, Damona Pharmaceuticals, Delix Therapeutics, EpiVario, Inc., Neumora Therapeutics, Inc., Rest Therapeutics, Tempero Bio, Inc., Terran Biosciences, Inc., Tetricus, Inc.; and is editor of Biological Psychiatry with income greater than $10,000. The remaining authors declare that they have no competing interests.
